Zymeworks

Zymeworks Net Margin

The Net Profit Margin of Zymeworks (ZYME) as of Oct 23, 2026 is -76.56 %. In the previous year, Net Profit Margin was -160.80 % — a change of -52.39% (higher).

Net Margin

-76.56 %

YoY

-52.39%

Last updated:

Net Profit Margin of Zymeworks is 2025 -76.56 % . Net Profit Margin of Zymeworks was 2024 -160.80 % . It decreases by -52.39% higher compared to the previous year.

For Zymeworks, the net margin of -76.6% is up versus -794.0% a few years ago.

The Zymeworks Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-68.95 USD
Jan 1, 2019
-492.27 USD
Jan 1, 2020
-463.54 USD
Jan 1, 2021
-794.01 USD
Jan 1, 2022
30.14 USD
Jan 1, 2023
-156.13 USD
Jan 1, 2024
-160.80 USD
Jan 1, 2025
-76.56 USD
The Zymeworks Net Margin history
YEARNet MarginYoY
-76.56 %-52.39%
-160.80 %+2.99%
-156.13 %-617.92%
30.14 %-103.80%
-794.01 %+71.29%
-463.54 %-5.84%
-492.27 %+613.97%
-68.95 %+242.97%
-20.10 %-93.45%
-307.10 %+54.75%
-198.45 %-74.39%
-774.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zymeworks Stock analysis

What does Zymeworks do? Zymeworks, Inc. generates revenue through its clinical-stage biopharmaceutical products and platforms. The company develops biotherapeutics using its Azymetric bispecific platform, which creates antibodies binding multiple targets, and its ZymeLink ADC platform, combining cytotoxins with tumor-targeting antibodies. Lead product ZW25 targets HER2 for cancer treatment, while ZW49 integrates ZW25 design with ZymeLink for enhanced therapy. These products are developed for clinical trials and potential commercialization, with revenue expected from future partnerships or sales once approved. Zymeworks focuses on oncology and immune modulation, leveraging its EFECT platform for immune cell recruitment control. The company’s platforms and product candidates are designed for pharmaceutical partnerships, with potential buyers including biopharmaceutical firms seeking innovative cancer therapies. Revenue streams will emerge from licensing agreements, milestone payments, and future product sales once clinical development progresses. The company’s product pipeline includes ZW25 and ZW49, both targeting HER2-related cancers. ZW25 uses Azymetric technology, while ZW49 incorporates ZymeLink for antibody-drug conjugates. These are developed for potential commercialization, with revenue anticipated from biopharmaceutical partners who license these technologies or products for further development and marketing. Zymeworks is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zymeworks stock

Net Profit Margin of Zymeworks is -76.56 % in 2025.

Net Profit Margin of Zymeworks changed from -160.80 % to -76.56 %, representing a -52.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Zymeworks since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Zymeworks with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Zymeworks

All Key Metrics — Zymeworks